Videos
February 24, 2021
Sagar Patel, MD, discusses utilization trends and survival outcomes among guideline-supported treatment options in older men with high-risk prostate cancer.
Videos
February 23, 2021
Tomasz Beer, MD, discusses results from a network meta-analysis comparing the efficacy of enzalutamide vs apalutamide, darolutamide, and bicalutamide for the treatment of nonmetastatic CRPC.
Videos
February 21, 2021
Ajeet Gajra, FACP, MD, discusses differences in referral patterns and treatment preferences between medical oncologists and urologists for patients with advanced prostate cancer.
Videos
February 21, 2021
Felix Feng, MD, discusses results from exploratory analysis of the phase 3 SPARTAN trial, which investigated potential biological signatures of patients with nonmetastatic CRPC who achieved long-term responses to apalutamide and placebo.
Videos
February 20, 2021
Hala Borno, MD, discusses observations from a research study that evaluated the implementation of a clinician-facing decision tool to help promote access to clinical trials for patients with prostate cancer.
Videos
February 19, 2021
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Videos
February 19, 2021
David Gill, MD, discusses the incidence and cost of radical prostatectomy for NCCN low-risk prostate cancer in the state of Utah.
Videos
February 19, 2021
Vidit Sharma, MD, discusses a study exploring whether reductions in PSA screening are responsible for increased incidence of metastatic prostate cancer in the United States.
Videos
February 19, 2021
Eric Schwartz, MD, discusses results from an analysis examining out-of-pocket costs for patients with prostate cancer prescribed abiraterone or enzalutamide.
Videos
February 19, 2021
Petros Grivas, MD, PhD, discusses results from a qualitative interview study evaluating the adoption of avelumab first-line maintenance therapy as standard of care for metastatic urothelial cancer in the United States.
Videos
February 19, 2021
Shilpa Gupta, MD, discusses patient characteristics and survival outcomes by PTEN loss of function status among patients with metastatic CRPC in real-world practice.
Videos
February 18, 2021
Vidit Sharma, MD, discusses results from a cost-effectiveness analysis comparing pembrolizumab with radical cystectomy or salvage intravesical chemotherapy for patients with BCG-unresponsive carcinoma in situ of the bladder.
Videos
February 18, 2021
Daniel Lage, MD, MSc, discusses study findings showing hospitalized patients with advanced genitourinary cancers had significantly greater functional impairment and worse survival compared to those with other cancer types.
Conference Coverage
February 16, 2021
Results from a real-world study highlight the clinical and resource utilization burden of adverse events among patients with prostate cancer treated with apalutamide and enzalutamide.
Conference Coverage
February 16, 2021
Findings from a real-world study show abiraterone is associated with greater risk of cardiovascular-related hospitalizations among men with prostate cancer than enzalutamide.
Videos
February 15, 2021
Kim Chi, MD, FRCPC, discusses 4-year efficacy and safety results from the phase 3 TITAN trial, which evaluated apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving ADT.
Videos
February 13, 2021
Fred Saad, MD, discusses final results from the phase 3 ACIS trial, which compared apalutamide vs placebo in combination with abiraterone acetate plus prednisone in metastatic CRPC.